Suven Life Sciences, a biopharmaceutical company, witnessed a rise in share price on Tuesday after the company announces today that the grant of one product patent from Israel (198821), one product patent from Macau (J/001515) and one product patent from USA (9018231) corresponding to their New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

Shares of the company are trading at Rs 248.30, up Rs 5.3, or 2.18% at the Bombay Stock Exchange (BSE) on Tuesday at 10:31 a.m.

Total volume of shares traded on the bourses today was higher by 96.77% to 268,935 compared with 22-day average volume of 136,676.